Roche to Acquire NimbleGen Systems for $272.5M in Cash; Expects to Close Deal in Q3

Following the transaction, NimbleGen will operate with some autonomy, continuing with its pre-existing plans to add to its portfolio higher-density arrays, integrated instrument systems, and related reagents and consumables for advanced genome analysis.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.